11) In the current study, we have investigated how IL-1B from tumour cells and the microenvironment interact to affect primary tumour growth and bone metastasis through regulation of the immune system, and whether targeting IL-1 driven changes to the immune response improves standard of care therapy for breast cancer bone metastasis. |
PMID:34290237 DOI:10.1038/s41523-021-00305-w |
2021 NPJ breast cancer |
* IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. |
- Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that production of the pro-inflammatory cytokine interleukin-1B (IL-1B) by breast cancer cells drives bone metastasis in patients and in preclinical in vivo models. In the current study, we have investigated how IL-1B from tumour cells and the microenvironment interact to affect primary tumour growth and bone metastasis through regulation of the immune system, and whether targeting IL-1 driven changes to the immune response improves standard of care therapy for breast cancer bone metastasis. Using syngeneic IL-1B/IL1R1 knock out mouse models in combination with genetic manipulation of tumour cells to overexpress IL-1B/IL1R1, we found that IL-1B signalling elicited an opposite response in primary tumours compared with bone metastases. In primary tumours, IL-1B inhibited growth, by impairing the infiltration of innate immune cell subsets with potential anti-cancer functions but promoted enhanced tumour cell migration. In bone, IL-1B stimulated the development of osteolytic metastases. In syngeneic models of breast cancer, combining standard of care treatments (Doxorubicin and Zoledronic acid) with the IL-1 receptor antagonist Anakinra inhibited both primary tumour growth and metastasis. Anakinra had opposite effects on the immune response compared to standard of care treatment, and its anti-inflammatory signature was maintained in the combination therapy. These data suggest that targeting IL-1B signalling may provide a useful therapeutic approach to inhibit bone metastasis and improve efficacy of current treatments for breast cancer patients. |
(1)85 ![]() |
(12)4 ![]() |
(25)2 ![]() |
(36)2 ![]() |
(2)71 ![]() |
(13)4 ![]() |
(26)2 ![]() |
(37)2 ![]() |
(3)51 ![]() |
(14)4 ![]() |
(27)2 ![]() |
(38)2 ![]() |
(4)33 ![]() |
(15)4 ![]() |
(28)2 ![]() |
(39)2 ![]() |
(5)26 *null* | (16)3 ![]() |
(29)2 ![]() |
(40)2 ![]() |
(6)12 ![]() |
(19)3 ![]() |
(30)2 ![]() |
(41)2 ![]() |
(7)8 ![]() |
(20)3 ![]() |
(31)2 ![]() |
(42)2 ![]() |
(8)7 ![]() |
(21)3 ![]() |
(32)2 ![]() |
(43)2 ![]() |
(9)5 ![]() |
(22)3 ![]() |
(33)2 ![]() |
|
(10)4 ![]() |
(23)3 ![]() |
(34)2 ![]() |
|
(11)4 ![]() |
(24)2 ![]() |
(35)2 ![]() |
add keyword